Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 19, 2018
Pharmacy Choice - News - Over-the-Counter Drugs - November 19, 2018

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 32     Next >>     Go To Page:

11/19/18 - Innovus Pharmaceuticals Acquires Worldwide Rights to Four Products from Boston Topicals, LLC
Innovus Pharmaceuticals, Inc.,, an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter and consumer care products to improve men s and women's health and respiratory diseases, announced today that the Company has acquired four branded topical products from Boston Topicals, LLC, expanding
11/18/18 - Idrasil Could Be The First Standardized Medical Marijuana Prescription Pill
Steele Clarke Smith III is chairman and CEO of C3 International, a post-proof of concept, pre-revenue life sciences company specializing in cannabinoid therapeutics. C3's pioneering patient, a 21- year-old San Diego man, came monthly from San Diego for raw cannabis and capsules prepared for him, Smith said. As part of a wider DEA operation in South
11/17/18 - FDA Approves Novartis Drug Promacta for First-Line SAA and Grants Breakthrough Therapy Designation for Additional New Indication
*Promacta is the first new treatment in decades for newly diagnosed SAA patients in the US; a decision by the European Medicines Agency is expected in 2019. "Severe aplastic anemia can be a fatal diagnosis if left untreated, and many patients fail to respond to current initial treatment options," said Liz Barrett, CEO, Novartis Oncology. The FDA's
11/16/18 - Active Pharmaceutical Ingredients Market USD 219,601.9 billion by 2020
The report on "Active Pharmaceutical Ingredients Market" helps you to understand the market size, share, growth, trends, major companies performance data and market opportunities. Active Pharmaceutical Ingredients market and its meteoric rise from 2010. Ever-rising war between man and diseases has seen an upward rise in the recent years.
11/16/18 - Elanco plant's new owner to get bond financing [The Augusta Chronicle, Ga.]
Nov. 16 Economic development officials gave tacit approval Thursday to transfer a $200 million industrial revenue bond for Augusta's Elanco animal pharmaceuticals plant to its new Brazil- based owner. The Augusta Economic Development Authority board voted to transfer Elanco's tax-exempt bonds to Union Agener, the U.S. subsidiary of a Sao Paulo- b
11/16/18 - FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication
Novartis announced today that the US Food and Drug Administration has expanded the label for Promacta to include first-line treatment for adults and pediatric patients two years and older with SAA in combination with standard immunosuppressive therapy. "Severe aplastic anemia can be a fatal diagnosis if left untreated, and many patients fail
11/16/18 - FDA: Nominations for Individuals and Consumer Organizations for Advisory Committees
The Food and Drug Administration issued a notice in the Federal Register by Associate Commissioner for Policy Leslie Kux entitled "Request for Nominations for Individuals and Consumer Organizations for Advisory Committees". A summary of the notice, published in the Federal Register on Nov. 16, states: The Food and Drug Administration is requesting
11/16/18 - GNW-News: FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication (english)
FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication. Novartis International AG/ FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication. Processed and transmitted by West Corporation.
11/16/18 - Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
Novartis International AG/ Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/ HER2- locally advanced or metastatic breast cancer. Processed and transmitted by West Corporation. "Today's CHMP opinion brings us one step closer to providing more women with HR+/ HER2- advanced breast cancer in Europ
11/16/18 - Request for Nominations for Individuals and Consumer Organizations for Advisory Committees
Agency: " Food and Drug Administration, HHS." ADDRESSES: All statements of interest from consumer organizations interested in participating in the selection process should be submitted electronically to ACOMSSubmissions@fda.hhs.gov, by mail to Advisory Committee Oversight and Management Staff, 10903 New Hampshire Ave., Bldg. 32, Rm. 5122, Silver Sp
11/15/18 - FDA unveils new mobile app for real-world patient data collection [Tehran Times (Iran)]
The Food and Drug Administration has launched a new mobile app for capturing real-world data from patients to inform and assist clinicians in making regulatory decisions. Partnering with Kaiser Permanente on a pilot study, the FDA evaluated the functionality and engagement of its MyStudies app. It is expected that the MyStudies app will aid researc
11/15/18 - HEALTH & SUPPORT
Monday evenings at 63 Jefferson Ave., Salem; and from noon to 1:30 p.m. Fridays at 75 Lindall St., Danvers. The Beverly and Addison Gilbert Hospital's Speakers Bureau is a free service designed to bring timely information on a variety of health-related topics. Held 7-8: 30 p.m. on the last Wednesday of each month in the doctors' conference room at
11/15/18 - Increased Consumer Risks From Purchasing Erectile Dysfunction Medicine on the Gray Market Exposed in New Research
Bayer and the National Consumers League release white paper that explores the risks consumers face when purchasing erectile dysfunction medicines from illegal online pharmacies and provides policy recommendations for increasing safe access to ED medicines. Bayer and the National Consumers League today released a white paper, Increased Consumer Risk
11/15/18 - Mitsubishi Tanabe Pharma Group Companies To Present New Data On Investigational Oral Formulation Of Edaravone For ALS At 29th International Symposium On ALS/MND
Mitsubishi Tanabe Pharma America, Inc. today announced that Mitsubishi Tanabe Pharma group companies will present pharmacokinetic data on an investigational oral suspension formulation of edaravone for the treatment of amyotrophic lateral sclerosis at the 29 th International Symposium on ALS/MND being held December 7-9 in Glasgow, Scotland.
11/15/18 - Nasal Spray Market 2018 Rise at CAGR of ~6.3% With ADAPT Pharma, Inc., Sandoz International GmbH, Bayer AG, Mylan N.V., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Catalent, Inc
"\"Nasal Spray\ "" Global Nasal Spray Market is expected to reach a CAGR of 6.3% in the forecast period 2018 to 2025. ADAPT Pharma, Inc., Sandoz International GmbH, INNOVUS PHARMACEUTICALS, INC., Cipla Inc., Aurena, J Pharmaceuticals, Bayer AG, St. Renatus, ARIUS FORMULATIONS PVT LTD, Ultratech India Limited, GlaxoSmithKline plc, Egalet Corporation
11/15/18 - NetworkNewsBreaks BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Developing a Personalized Advanced Breast Cancer Treatment
BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, is currently developing a personalized immunotherapy drug to treat advanced breast cancer. A recent article further discussing the company reads, Based on its research results, the company is developing a second immunotherapy
11/15/18 - Santen Expands Research and Development Leadership Team with Additions of Reza M. Haque, MD, PhD and Peter Sallstig, MD, MBA
Santen Inc., a U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, today announced the expansion of its research and development leadership team through the addition of two new executive hires. Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Developmen
11/14/18 - AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
AbbVie, a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc., today presented for the first time additional results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of elagolix in women with uterine fibroids. These results were presented at the 47 th American...
11/14/18 - Increased Consumer Risks from Purchasing Erectile Dysfunction Medicine on the Gray Market Exposed in New Research
Bayer and the National Consumers League today released a white paper, Increased Consumer Risk from Erectile Dysfunction Medication Advertised and Sold on the Gray Market, which exposes the dangers to consumers who purchase ED medication from illegal online pharmacies also known as the gray market. The white paper was commissioned by Bayer, and
11/14/18 - Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately $7.4 Million for the Third Quarter 2018 and $19.2 Million for the First Nine Months of 2018
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men s and women s health and respiratory diseases, announced today its reported results for the third quarter 2018.. Revenues of approximately $7.4 mill
11/14/18 - INNOVUS PHARMACEUTICALS, INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Innovus Pharmaceuticals, Inc., together with its subsidiaries, are collectively referred to as "Innovus", the "Company", "us", "we", or "our". The following information should be read in conjunction with the condensed consolidated financial statements and notes thereto appearing elsewhere in this report. For additional context with which to underst
11/14/18 - INTRICON CORP - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Headquartered in Arden Hills, Minnesota, IntriCon Corporation is an international company engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. In addition to its operations in Minnesota, the Company has facilities in Illinois, Singapore, Indonesia, Germany and the United Kingdom. The Company sold the card
11/14/18 - SKINVISIBLE INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995,
11/13/18 - Cumberland Pharmaceuticals Reports Third Quarter 2018 Financial Results
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2018 financial results and Company update. Cumberland has a portfolio of eight U.S. Food and Drug Administration approved brands. "Our team has been very busy during the
11/13/18 - DiaMedica Therapeutics in Plymouth files for additional stock offering [Star Tribune (Minneapolis)]
Nov. 13 A Plymouth biopharmaceutical company, DiaMedica Therapeutics Inc., is proposing a stock offering to raise $15 million for the development and commercialization of a new drug to treat neurological and kidney diseases. "We have made significant progress in positioning DM199 to treat patients with stroke and kidney diseases," said Rick Paul
Articles(s): 1 - 25 of 32     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415